Corcept Therapeutics Incorporated (CORT)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 60.36% | 58.78% | 59.10% | 59.07% | 60.62% | 62.76% | 63.43% | 64.32% | 65.12% | 73.01% | 81.15% | 89.86% | 98.42% | 98.38% | 98.29% | 98.17% | 98.20% | 98.02% | 97.95% | 97.96% |
| Operating profit margin | 22.24% | 21.80% | 23.09% | 24.34% | 28.03% | 31.89% | 33.44% | 34.61% | 34.01% | 33.53% | 31.13% | 32.38% | 36.23% | 37.27% | 40.14% | 38.93% | 36.42% | 35.56% | 34.08% | 33.84% |
| Pretax margin | 25.82% | 24.89% | 25.37% | 26.06% | 28.93% | 32.37% | 33.66% | 34.68% | 34.14% | 33.72% | 31.49% | 33.02% | 37.18% | 38.55% | 41.65% | 40.54% | 38.07% | 37.19% | 35.60% | 35.20% |
| Net profit margin | 22.00% | 20.31% | 22.10% | 22.84% | 25.24% | 29.39% | 28.76% | 29.41% | 30.74% | 30.17% | 28.45% | 29.23% | 29.96% | 30.73% | 32.49% | 31.64% | 30.73% | 30.41% | 29.15% | 29.50% |
Corcept Therapeutics Inc has consistently demonstrated strong profitability over the quarters presented with consistently high gross profit margins ranging from 98.62% to 98.68%. The company's operating profit margins have shown some fluctuations but remained relatively healthy, ranging from 21.80% to 34.61%. Despite this variability, the operating profit margins indicate that the company has been effective in managing its operating expenses.
The pretax margins have also shown some variability but have generally been robust, ranging from 24.89% to 34.70%. This suggests that Corcept Therapeutics Inc has been successful in generating profits before accounting for taxes across the quarters.
Similarly, the net profit margins have been strong, ranging from 20.31% to 29.41%, indicating that the company has been efficient in managing its bottom line and delivering profits for its shareholders after accounting for all expenses and taxes.
Overall, the high gross profit margins coupled with solid operating, pretax, and net profit margins suggest that Corcept Therapeutics Inc has been successful in maintaining profitability and generating returns for its investors over the periods analyzed.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 17.26% | 16.52% | 18.85% | 16.30% | 19.31% | 23.78% | 26.41% | 28.11% | 29.37% | 20.21% | 18.79% | 19.94% | 22.42% | 24.85% | 28.32% | 29.26% | 27.07% | 27.65% | 27.83% | 27.31% |
| Return on assets (ROA) | 17.08% | 15.38% | 18.03% | 15.30% | 17.38% | 21.92% | 22.71% | 23.89% | 26.55% | 18.18% | 17.17% | 18.00% | 18.54% | 20.48% | 22.92% | 23.79% | 22.84% | 23.65% | 23.80% | 23.80% |
| Return on total capital | 21.17% | 21.25% | 23.45% | 19.02% | 22.44% | 26.79% | 29.64% | 32.27% | 33.12% | 21.90% | 20.44% | 21.56% | 24.50% | 27.10% | 31.08% | 31.84% | 30.07% | 30.35% | 30.68% | 30.61% |
| Return on equity (ROE) | 20.95% | 19.79% | 22.44% | 17.84% | 20.21% | 24.69% | 25.49% | 27.43% | 29.94% | 19.71% | 18.67% | 19.46% | 20.26% | 22.34% | 25.15% | 25.88% | 25.37% | 25.96% | 26.24% | 26.67% |
Corcept Therapeutics Inc has shown consistent profitability over the quarters based on the profitability ratios analyzed. The company's Operating ROA has been relatively stable with a range of 16.30% to 19.31%, indicating the effectiveness of management in generating operating income relative to its total assets. The ROA, which reflects overall profitability, has also been steady ranging from 15.30% to 17.38%.
The Return on Total Capital has shown a similar trend, ranging from 19.02% to 23.45%. This ratio indicates the efficiency of the company in generating profits from both equity and debt capital invested in the business. Additionally, the Return on Equity (ROE) has been consistent, ranging from 17.84% to 22.44%, demonstrating the company's ability to generate profit from shareholders' equity.
Overall, Corcept Therapeutics Inc has maintained robust profitability ratios, signaling efficient asset utilization, effective management of capital, and attractive returns for both asset and equity investors over the analyzed quarters.